Skip to main content
Clinical Trials/NCT06943690
NCT06943690Not yet recruitingNot Applicable

Safety and Efficacy Study of Single-port Robotic Versus Multi-port Robotic Radical Rectal Cancer Surgery: A Multi-center, Prospective, Open Label, Non-inferiority, Randomized Controlled Trial

Ruijin Hospital4 sites in 1 country212 target enrollmentStarted: May 1, 2025Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
212
Locations
4
Primary Endpoint
Surgical success rate

Study Overview

Brief Summary

This study is designed to evaluate the safety and efficacy of single-port robotic surgery compared to multi-port robotic surgery for rectal cancer.

Detailed Description

Surgical robots were born in the 1980s and have the advantages of being precise, flexible, less invasive and remotely operable than traditional surgical methods. The single-port robot is a further extension of minimally invasive surgery by placing multiple instruments through a single incision. Most studies have reported on the perioperative outcomes of robotic versus conventional laparoscopic surgery in the treatment of colorectal cancer. However, there are limited data comparing the perioperative outcomes of single-port robotics and multi-port robotics in the treatment of colorectal cancer,especially in rectal cancer surgery. The purpose of this study is to evaluate the safety and efficacy of single-port robotic surgery compared to multi-port robotic surgery for rectal cancer.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •18 years < age ≤80 years
  • •Tumor located in the mid to high rectum (lower edge of tumor ≥ 5 cm from anal verge)
  • •Pathological rectal carcinoma
  • •Clinically diagnosed c/ycT1-3N0-1M0 lesions according to the 8th Edition of AJCC Cancer Staging Manual
  • •Tumor size of 10 cm or less
  • •No history of other malignant tumors
  • •ECOG score is 0-1
  • •ASA score is Ⅰ-Ⅲ
  • •Informed consent

Exclusion Criteria

  • •Body mass index (BMI) >35 kg/m2
  • •Familial adenomatous polyposis (FAP)
  • •Inflammatory bowel disease (IBD)
  • •Multiple malignant colorectal tumors
  • •Pregnant woman or lactating woman
  • •Severe mental disease
  • •Previous gastrointestinal surgery (except appendectomy )
  • •Combination of intestinal obstruction, bleeding, perforation requiring emergency surgery
  • •Requirement of simultaneous surgery for other disease
  • •Serious disorders of liver and kidney function, coagulation function, or severe underlying diseases that cannot tolerate the surgery.
  • •Patients or family members who cannot understand the study program.

Arms & Interventions

Single-Port Robotic Surgery

Experimental

Patients with rectal cancer undergo single-port robotic surgery.

Intervention: Single-port robotic surgery (Procedure)

Multi-Port Robotic Surgery

Active Comparator

Patients with rectal cancer undergo multi-port robotic surgery.

Intervention: Multi-port robotic surgery (Procedure)

Outcomes

Primary Outcomes

Surgical success rate

Time Frame: intraoperative

Proportion of robotic procedures not converted to laparoscopic or open surgery

Secondary Outcomes

  • Lymph node detection(14 days after surgery)
  • Operative time(intraoperative)
  • Intraoperative blood loss(intraoperative)
  • Incision length(intraoperative)
  • Total incision length(intraoperative)
  • Length of stay(1-30 days after surgery)
  • Postoperative recovery course(1-14 days after surgery)
  • Early morbidity rate(30 days after surgery)
  • Pain score(1-3 days after surgery)
  • Tumor size(14 days after surgery)
  • Incisal margin(14 days after surgery)
  • Cosmetic effect(1 month, 6 months and 1 year after surgery)
  • The quality of life-Colorectal(1 month, 6 months and 1 year after surgery)
  • disease free survival rate(12 months after surgery)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Zhao Ren

Chief Physicion

Ruijin Hospital

Study Sites (4)

Loading locations...

Similar Trials